^
2ms
NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov)
P1, N=221, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete
Trial completion date • Trial termination • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)
3ms
ENDURE: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (clinicaltrials.gov)
P2, N=51, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
4ms
Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
4ms
Enrollment change • Trial withdrawal • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
FoundationOne® CDx
|
carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
5ms
Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
FoundationOne® CDx
|
carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
7ms
Enrollment change • Combination therapy
|
CD4 (CD4 Molecule)
|
cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)
8ms
EA5163: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (clinicaltrials.gov)
P3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pemfexy (pemetrexed)
9ms
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
P3, N=304, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2024
Enrollment open • Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
9ms
Phase classification • Combination therapy
|
Avastin (bevacizumab) • carboplatin • pemetrexed • Ensacove (ensartinib) • Pemfexy (pemetrexed)
10ms
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=18, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date • Surgery
|
cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
10ms
NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker • Checkpoint block
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
11ms
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=18, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Surgery
|
cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
11ms
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Pemfexy (pemetrexed) • papaverine
11ms
Enrollment change • Trial withdrawal • Combination therapy • Metastases
|
cisplatin • carboplatin • Lorbrena (lorlatinib) • pemetrexed • Pemfexy (pemetrexed)
12ms
Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
12ms
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=10, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Sep 2024
Trial completion date
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
ALK positive • MET amplification • ALK rearrangement
|
cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
1year
New P3 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
1year
Enrollment open • Circulating tumor DNA • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)
1year
Enrollment open • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
1year
Trial suspension • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
over1year
Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
P2, N=35, Recruiting, Liza Villaruz, MD | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Apr 2027 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: May 2025 --> Sep 2025
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
over1year
New P2 trial • Combination therapy • Metastases
|
cisplatin • carboplatin • Lorbrena (lorlatinib) • pemetrexed • Pemfexy (pemetrexed)
over1year
Enrollment closed • Enrollment change • Surgery
|
cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
over1year
NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=221, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)
over1year
NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
Trial completion date • Trial primary completion date • Checkpoint inhibition • Checkpoint block
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
over1year
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR mutation • ALK mutation
|
cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
over1year
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
P1/2, N=25, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2026
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
over1year
Enrollment closed • Enrollment change • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)
over1year
Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
P2, N=35, Not yet recruiting, Liza Villaruz, MD | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2025
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
over1year
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (clinicaltrials.gov)
P3, N=846, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Dec 2028 | Trial primary completion date: Sep 2023 --> Dec 2028
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pemfexy (pemetrexed)
over1year
Enrollment change • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • ALK mutation • ROS1 mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
over1year
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
P1/2, N=25, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
over1year
New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
almost2years
New P2 trial • Circulating tumor DNA • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)
almost2years
GEOMETRY-E: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (clinicaltrials.gov)
P3, N=6, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Novartis decided to halt enrolment for this study on 11-May-2022. This decision was based on a business decision and not related with any safety concerns.
Trial termination • Combination therapy • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET amplification • EGFR T790M negative
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib) • Pemfexy (pemetrexed)
almost2years
New P3 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
EGFR mutation • ALK rearrangement • ROS1 rearrangement • TROP2 positive
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
almost2years
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
almost2years
ENDURE: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (clinicaltrials.gov)
P2, N=51, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2024
Enrollment open • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement
|
carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
almost2years
New P3 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR mutation • ALK mutation
|
cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
2years
Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET amplification • EGFR T790M negative
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib) • Pemfexy (pemetrexed)
2years
Enrollment closed • Checkpoint inhibition • Checkpoint block
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
2years
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
P1/2, N=25, Not yet recruiting, Vanderbilt-Ingram Cancer Center | Initiation date: Sep 2022 --> Jan 2023
Trial initiation date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)